Comparable stake leader
5AM Ventures V, L.P.
SEC ownership of Entrada Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001689375.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
08 Sep 2026
- Public ticker
- TRDA on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
5AM Ventures V, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
5AM Ventures V, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
08 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001689375
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Entrada Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
5AM Ventures V, L.P.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
08 Sep 2026
3/4/5
13D/G
13F
Lead comparable stake: 11%
13D/G row: 5AM Ventures V, L.P.
Showing 1-8 of 50 holder rows.
Quick read
5AM Ventures V, L.P. leads the comparable SEC ownership view at 11%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens 5AM Ventures V, L.P.'s linked filing trail.
Comparable ownership
Top 5
5AM Ventures V, L.P.
11%
MPM BioVentures 2014, L.P.
9.9%
ROCHE FINANCE LTD
6.9%
BlackRock, Inc.
5.3%
Janus Henderson Group Ltd.
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P. |
3/4/5
13D/G
10%+ Owner · Kush Parmar
|
11%
from 13D/G
|
$27,115,682
3,877,094 shares
|
-$2,998,857 | 06 Aug 2026 |
| MPM BioVentures 2014, L.P. |
13D/G
3/4/5
ANSBERT GADICKE · 10%+ Owner
|
9.9%
|
$28,205,935
3,885,115 shares
|
$0 | 08 Sep 2026 |
| ROCHE FINANCE LTD |
13D/G
|
6.9%
|
$23,019,270
2,569,115 shares
|
$0 | 31 Dec 2024 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.3%
from 13D/G
|
$19,013,332
2,583,333 shares
|
— | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
4%
|
$9,964,391
1,521,281 shares
|
-$3,932,443 | 30 Jun 2025 |
| TCG Crossover GP I, LLC |
13D/G
|
2.7%
|
$7,803,293
1,060,230 shares
|
-$6,308,359 | 30 Jun 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
0.9%
from 13D/G
|
$3,992,000
542,316 shares
|
— | 30 Jun 2026 |
| BAKER BROS. ADVISORS LP |
3/4/5
13F
10%+ Owner · Company
|
12%
|
$42,564,061
4,691,392 shares
|
+$1,614,433 | 20 Nov 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$59,259,574.
Buys
$1,643,749
Insiders: 2
Sells
$60,903,323
Insiders: 23
Net
-$59,259,574
Shares: -8,074,631
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 211,911
Shares: 8,286,542
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 7,794,750 | $0 | $56,125,212 | -$56,125,212 |
| 3-6 | 5,000 | 40,907 | $29,316 | $628,763 | -$599,447 |
| 6-9 | 0 | 41,975 | $0 | $540,417 | -$540,417 |
| 9-12 | 206,911 | 408,910 | $1,614,433 | $3,608,932 | -$1,994,499 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 35 reporting-owner rows connected to Entrada Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
35
Largest Forms 3/4/5 holder
ROCHE HOLDING LTD
Net 12M change
-$59,259,579
Latest report
04 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| ROCHE HOLDING LTD | 10%+ Owner | $44,988,265 | Mixed | 02 Nov 2021 | ||
| BAKER BROS. ADVISORS LP | 10%+ Owner | $42,564,061 | +$1,614,433 | +3.9% | Filing P/S | 20 Nov 2025 |
| Redmile Group, LLC | 10%+ Owner | $31,251,176 | Mixed | 02 Nov 2021 | ||
| Ansbert Gadicke | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM Asset Management Investors BV2014 LLC | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BioVentures 2018 GP LLC | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BIOVENTURES 2018, L.P. | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| Luke Evnin | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BioVentures 2014, L.P. | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| Todd Foley | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BioVentures 2014 GP LLC | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BioVentures 2014 LLC | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BioVentures 2018 LLC | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BioVentures 2014 (B), L.P. | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| MPM BIOVENTURES 2018 (B), L.P. | 10%+ Owner | $27,700,869 | -$3,600,470 | -12% | Filing P/S | 04 Sep 2026 |
| Scott M. Rocklage | 10%+ Owner | $27,115,682 | -$1,238,857 | -4.4% | Mixed | 06 Aug 2026 |
| 5AM Ventures V, L.P. | 10%+ Owner | $27,115,682 | -$2,998,857 | -10% | Mixed | 06 Aug 2026 |
| 5AM Partners V, LLC | 10%+ Owner | $27,115,682 | -$1,238,857 | -4.4% | Mixed | 06 Aug 2026 |
| 5AM Opportunities I (GP), LLC | 10%+ Owner | $27,115,682 | -$1,238,857 | -4.4% | Mixed | 06 Aug 2026 |
Recent insider transactions for Entrada Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BIOVENTURES 2018, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.74% | $205,608 | $7.13 | -28,837 | 3,885,115 | 09 Sep 2026 | See Footnote |
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BIOVENTURES 2018, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -4.69% | $1,426,425 | $7.41 | -192,500 | 3,913,952 | 08 Sep 2026 | See Footnote |
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BIOVENTURES 2018, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.93% | $273,735 | $7.11 | -38,500 | 4,106,452 | 04 Sep 2026 | See Footnote |
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| Mpm Bioventures 2018, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BIOVENTURES 2018, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
| MPM BioVentures 2014, L.P. | TRDA | Common Stock | Sale | -0.77% | $231,326 | $7.17 | -32,263 | 4,144,952 | 03 Sep 2026 | See Footnote |
* marks a reported price that did not pass the local price check.